Centessa Pharmaceuticals (CNTA)
(Delayed Data from NSDQ)
$17.02 USD
-0.16 (-0.93%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $17.00 -0.02 (-0.12%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Fundamental Charts
About Return on Equity (TTM)
Centessa Pharmaceuticals PLC Sponsored ADR's return on equity, or ROE, is -40.22% compared to the ROE of the Medical - Drugs industry of -57.32%. While this shows that CNTA has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
CNTA 17.02 -0.16(-0.93%)
Will CNTA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CNTA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CNTA
Centessa Pharmaceuticals (CNTA) Upgraded to Buy: What Does It Mean for the Stock?
Wall Street Analysts Think Centessa Pharmaceuticals (CNTA) Could Surge 138.77%: Read This Before Placing a Bet
CNTA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for CNTA
Centessa Pharmaceuticals (CNTA) Maintains Buy Rating and $30 PT | CNTA Stock News
Alkermes narcolepsy trial results 'encouraging' for Centessa, says Leerink
Centessa Pharmaceuticals (CNTA) Gains Coverage with a 'Buy' Rating | CNTA Stock News
Truist Initiates Coverage on Centessa (CNTA) with Promising Outlook | CNTA Stock News
Centessa initiated with bullish view at Truist, here's why